Loading…
Loading…
Home › All recalls › Prescription medicine
Category
Prescription drugs recalled for contamination, potency or labelling.
Or try another category
2,003 recalls · newest first
Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.
Microbial contamination of Non-Sterile Product; presence of yeast identified as Candida parapsilosis
Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals.
Subpotent: Out of Specification result observed for low assay
Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials.
Incorrect/Undeclared Excipients.
Failed Impurities/Degradation Specifications: Out of Specification results in the repackaged product for impurities at the 12-month time point.
Superpotent/Subpotent single ingredient Drug: Out of Specification Assay results
Labeling: Label Error on Declared Strength: The incorrect label on the back of the product packaging.
CGMP Deviations
CGMP Deviations
Non-Sterility
CGMP Deviations
Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets,…
Labeling: Label Mix-Up- Bottles labeled as Digoxin Tablets, USP 0.125 mg contain Digoxin Tablets, USP 0.25mg and bottles labeled as Digoxin Tablets,…
Stability data does not support expiry: Shelf-life of the impacted lots of BD ChloraPrep" Clear 1 mL Applicator cannot be substantiated beyond…
Marketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with sildenafil, an ingredient found in a FDA approved product…
CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.
Defective Container: slow leakage under the cap
Lack of Assurance of Sterility: out-of-specification test results observed for Filter Integrity Test (FIT).